Transforming growth factor beta engages TACE/ADAM17 and ErbB3 to activate PI3K/Akt in HER2-overexpressing breast cancer and desensitizes cells to trastuzumab

被引：0
|
作者：
Wang, E. [1 ]
Xiang, B. [1 ]
Olivares, M. G. [1 ]
Chang, C. [1 ]
Arteaga, C. L. [1 ]
机构：
[1] Vanderbilt Univ, Nashville, TN USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：72S / 72S
页数：1
相关论文
共 50 条
  • [21] Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer
    Zhang, Long
    Zhou, Fangfang
    ten Dijke, Peter
    TRENDS IN BIOCHEMICAL SCIENCES, 2013, 38 (12) : 612 - 620
  • [22] The role of the ErbB3/PI3K/AKT pathway in determining breast cancer cell sensitivity against the irreversible dual EGFR/ErbB2 inhibitor EKB-569
    Shabbir, W.
    Bruenner-Kubarth, C.
    Grusch, M.
    Berger, W.
    Marian, B.
    Wagner, R.
    Loetsch, D.
    Zielinski, C. C.
    Grunt, T. W.
    EJC SUPPLEMENTS, 2008, 6 (12): : 176 - 176
  • [23] Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells
    Joshi, Jayashree P.
    Brown, Nicole E.
    Griner, Samantha E.
    Nahta, Rita
    BIOCHEMICAL PHARMACOLOGY, 2011, 82 (09) : 1090 - 1099
  • [24] ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway
    Lin, Ping
    Sun, Xicai
    Feng, Tian
    Zou, Haifeng
    Jiang, Ying
    Liu, Zijun
    Zhao, Dandan
    Yu, Xiaoguang
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2012, 359 (1-2) : 235 - 243
  • [25] Effect of trastuzumab on the antiproliferative effects of PI3K inhibitors in HER2+breast cancer cells with de novo resistance to trastuzumab.
    Espin, Estefania
    Alejandro Perez-Fidalgo, Jose
    Tormo, Eduardo
    Pineda, Begona
    Miguel Cejalvo, Juan
    Sabbaghi, MohammadA
    Alonso, Elisa
    Rovira, Ana
    Rojo, Federico
    Albanell, Joan
    Bermejo, Begona
    Burgues, Octavio
    Eroles, Pilar
    Lluch, Ana
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway
    Ping Lin
    Xicai Sun
    Tian Feng
    Haifeng Zou
    Ying Jiang
    Zijun Liu
    Dandan Zhao
    Xiaoguang Yu
    Molecular and Cellular Biochemistry, 2012, 359 : 235 - 243
  • [27] Demethoxycurcumin induces apoptosis in HER2 overexpressing bladder cancer cells through degradation of HER2 and inhibiting the PI3K/Akt pathway
    Kao, Chien-Chang
    Cheng, Yi-Ching
    Yang, Ming-Hsin
    Cha, Tai-Lung
    Sun, Guang-Huan
    Ho, Chi-Tang
    Lin, Ying-Chao
    Wang, Hao-Kuang
    Wu, Sheng-Tang
    Way, Tzong-Der
    ENVIRONMENTAL TOXICOLOGY, 2021, 36 (11) : 2186 - 2195
  • [28] ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway
    Xiang-jun Wang
    Chang-wei Feng
    Min Li
    Molecular and Cellular Biochemistry, 2013, 380 : 57 - 66
  • [29] ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway
    Wang, Xiang-jun
    Feng, Chang-wei
    Li, Min
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2013, 380 (1-2) : 57 - 66
  • [30] Differential effects of erbB3 and IGF-1R signaling on lapatinib resistance acquired by the erbB2-overexpressing breast cancer cells refractory to trastuzumab
    Lyu, Hui
    Huang, Jingcao
    Lee, Youngseok
    Liu, Bolin
    MOLECULAR CANCER RESEARCH, 2013, 11
12345